Cargando…
Algorithmic Modeling Quantifies the Complementary Contribution of Metabolic Inhibitions to Gemcitabine Efficacy
Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a prodrug widely used for treating various carcinomas. Gemcitabine exerts its clinical effect by depleting the deoxyribonucleotide pools, and incorporating its triphosphate metabolite (dFdC-TP) into DNA, thereby inhibiting DNA synthesis. This process...
Autores principales: | Kahramanoğullari, Ozan, Fantaccini, Gianluca, Lecca, Paola, Morpurgo, Daniele, Priami, Corrado |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519828/ https://www.ncbi.nlm.nih.gov/pubmed/23239976 http://dx.doi.org/10.1371/journal.pone.0050176 |
Ejemplares similares
-
Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics
por: Lecca, Paola, et al.
Publicado: (2012) -
Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth
por: Lecca, Paola, et al.
Publicado: (2012) -
Mechanistic interplay between ceramide and insulin resistance
por: Reali, Federico, et al.
Publicado: (2017) -
Quantifying dynamic mechanisms of auto-regulation in Escherichia coli with synthetic promoter in response to varying external phosphate levels
por: Uluşeker, Cansu, et al.
Publicado: (2019) -
Gener: a minimal programming module for chemical controllers based on DNA strand displacement
por: Kahramanoğulları, Ozan, et al.
Publicado: (2015)